Valuation: Entrada Therapeutics, Inc.

Market Cap 248M 216M 200M 184M 347M 23.83B 355M 2.39B 935M 11.67B 930M 909M 40.19B P/E 2026 *
-1.7x
P/E 2027 * -1.81x
Enterprise Value 154M 135M 124M 115M 216M 14.83B 221M 1.49B 582M 7.26B 579M 566M 25.01B EV / Sales 2026 *
10.3x
EV / Sales 2027 * -2.81x
Free-Float
85.73%
Yield 2026 *
-
Yield 2027 * -
1 day+0.29%
1 week-6.89%
Current month-6.39%
1 month+6.00%
3 months-49.19%
6 months-37.36%
Current year-32.98%
1 week 6.46
Extreme 6.46
7.13
1 month 6.46
Extreme 6.46
8.1
Current year 5.63
Extreme 5.63
16.45
1 year 4.93
Extreme 4.93
16.45
3 years 4.93
Extreme 4.93
21.79
5 years 4.93
Extreme 4.93
36.85
10 years 4.93
Extreme 4.93
36.85
Manager TitleAgeSince
Chief Executive Officer 50 01/08/2017
Director of Finance/CFO 47 01/11/2020
President 56 01/01/2024
Director TitleAgeSince
Director/Board Member 50 01/08/2017
Chairman 44 01/12/2020
Director/Board Member 67 01/12/2020
Date Insider Type Main position Quantity % Market Cap.
6/10/26 A Free

Director

19,000 0.0489%
6/10/26 A Free

Director

19,000 0.0489%
6/10/26 A Free

Chairman

19,000 0.0489%
Change 5-day change 1-year change 3-year change Capi.($)
+0.29%-6.89%+7.99%-57.81% 248M
-7.17%-2.63%+49.59%+74.24% 55.98B
+0.24%-5.62%+54.73%+125.15% 53.69B
+0.80%-8.41%+3.57%+425.83% 23.29B
-0.09%-1.61%-18.68%-15.48% 23.15B
-5.95%-0.22%+35.96%-9.58% 20.58B
-1.14%-3.16%+32.88%-28.80% 17.76B
-5.16%-7.00%+177.56%+326.39% 16.09B
-6.91%+2.40%+36.86%+636.97% 15.93B
+0.43%-2.07%+24.79%+188.40% 14B
Average -2.47%-1.85%+40.53%+166.53% 24.07B
Weighted average by Cap. -2.91%-2.20%+43.55%+156.81%

Financials

2026 *2027 *
Net sales 14.99M 13.11M 12.1M 11.14M 21.01M 1.44B 21.47M 145M 56.58M 707M 56.29M 55.05M 2.43B 29.81M 26.06M 24.05M 22.16M 41.79M 2.87B 42.71M 288M 113M 1.41B 112M 109M 4.84B
Net income -176M -154M -142M -131M -246M -16.93B -252M -1.7B -664M -8.29B -660M -646M -28.55B -188M -164M -151M -139M -263M -18.06B -269M -1.81B -708M -8.84B -704M -689M -30.45B
Net Debt -93.49M -81.74M -75.44M -69.49M -131M -9B -134M -902M -353M -4.41B -351M -343M -15.18B -331M -290M -267M -246M -465M -31.91B -475M -3.2B -1.25B -15.62B -1.24B -1.22B -53.81B
Logo Entrada Therapeutics, Inc.
Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in establishing a class of medicines, which engages intracellular targets. Its Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the delivery of a range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. The Company is advancing a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases, among others. The Company is focused on the development of EEV therapeutics for rare neuromuscular diseases, including Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1). It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1. The Company has advanced two ocular programs into lead optimization for the potential treatment of inherited retinal diseases.
Employees
152
Date Price Change Volume
17/07/26 $6.890 +0.29% 378,186
16/07/26 $6.870 -3.38% 726,508
15/07/26 $7.110 +4.56% 282,714
14/07/26 $6.800 +3.03% 245,939
13/07/26 $6.600 -4.62% 284,674
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
6.870USD
Average target price
18.75USD
Spread / Average Target
+172.93%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. TRDA Stock